Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4535-4539

  Pesta, M ^a   Kulda, V ^a   Topolcan, O ^a   Safranek, J ^a   Vrzalova, J ^a   Cerny, R ^a   Holubec, Lubos ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

mRNA; Non small cell lung cancer; Promoter methylation; RECK; RT PCR; Tissue samples

Indexed keywords

GLYCOPROTEIN; MESSENGER RNA; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 75149170131     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H and Takahashi C: RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22(2-3): 167-175, 2003.
2. Dusek L, Muzik J, Kubasek M, Koptikova J, Zaloudik J, Vyzula R: Epidemiologie zhoubnych nadoru íCeske republice. Masarykova univerzita, 2005. Available at: http://www.svod.cz.ISSN 1802-8861. Accessed May 07, 2009.
3. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5): 584-594, 2008.
4. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564): 2387-2392, 2002.
5. Clark JC, Thomas DM, Choong PF and Dass CR: RECK - a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 26(3-4): 675-683, 2007.
6. Chang HC, Cho CY and Hung WC: Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res 66(17): 8413-8420, 2006.
7. Chang HC, Liu LT and Hung WC: Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cellular Signalling 16(6): 675-679, 2004.
8. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, Xiao S and Lu H: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88(72): 1358-1366, 2008.
9. Chang HC, Cho CY and Hung WC: Down-regulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 98(2): 169-173, 2007.
10. Pesta M, Topolcan O, Holubec L Jr, Rupert K, Cerna M, Holubec LS, Treska V, Finek J and Cerny R: Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-I and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 27(4A): 1863-1867, 2007.
11. Greenlee KJ, Werb Z and Kheradmand F: Matrix metallo-proteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 87(1): 69-98, 2007.
12. Elkington PT and Friedland JS: Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61(3): 259-266, 2006.
13. Konstantinopoulos PA, Karamouzis MV, Papatsoris AG and Papavassiliou AG: Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 40(6-7): 1156-1168, 2008.
14. Chirco R, Liu XW, Jung KK and Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25(1): 99-113, 2006.
15. Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, Topolcan O, Cerny R and Holubec L Jr: Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol 28(5): 247-252, 2007.
16. Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, Frias C, Diaz-Lopez A, Rodriguez-Jimenez FJ, Balibrea JL and Benito M: Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 77(1): 217-223, 2007.
17. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Creme E, Wurtz A, Porte H and Huet G: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 103(8): 1676-1684, 2005.
18. Takemoto N, Tada M, Hida Y, Asano T, Cheng S, Kuramae T, Hamada J, Miyamoto M, Kondo S and Moriuchi T: Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer 58(3): 376-383, 2007.
19. Takagi S, Simizu S and Osada H: RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 69(4): 1502-1508, 2009.
20. Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, Otake Y, Morioka Y, Takahashi C, Noda M, Wada H and Tanaka F: Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40(10): 1617-1623, 2004.
21. Takenaka K, Ishikawa S, Yanagihara K, Miyahara R, Hasegawa S, Otake Y, Morioka Y, Takahashi C, Noda M, Ito H, Wada H and Tanaka F: Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage HIA N2 non-small-cell lung cancer. Ann Surg Oncol 12(10): 817-824, 2005.